Account

New to ADSS? Open an
account now to get started.

OR

Already have an account?

Add funds to your ADSS account

Account

New to ADSS? Open an
account now to get started.

Add funds to your ADSS account

Trends & Analysis
News
Gold hits multi-week high amid a USD decline
News
Is Nike a buy for patient traders?
News
Tesla hits speed breaker in vehicle deliveries
News
EUR/USD ends Friday in the red
News
Nike’s shares decline despite upbeat Q1 results
News
Is Apple the last place to hide?
Trends & Analysis
News
Gold hits multi-week high amid a USD decline
News
Is Nike a buy for patient traders?
News
Tesla hits speed breaker in vehicle deliveries
News
EUR/USD ends Friday in the red
News
Nike’s shares decline despite upbeat Q1 results
News
Is Apple the last place to hide?

CFDs & spread bets are complex instruments & come with a high risk of losing money rapidly due to leverage. 73% of Retail investor accounts lose money when trading CFDs & spread bets with this provider. You should consider whether you understand how CFDs work & whether you can afford to take the high risk of losing your money.


Account
New to ADSS? Open an
account now to get started.
Open an account Login

News

Pfizer’s Q1 print injects optimism in investors

 

Wednesday, May 4, 2022

The news shaping the markets today

Around 101 Ukrainian civilians were evacuated from the tunnels of the Azovstal steel factory in the city of Mariupol. The RUB/USD forex pair traded slightly lower on the news.


Australia’s retail sales grew 1.6% in March, versus 1.8% growth in the previous month. Retail sales climbing for the third straight month sent the AUD/USD pair higher in forex trading this morning.


New Zealand’s unemployment rate came in unchanged at an all-time low of 3.2% in the first quarter. The latest reading was in-line with market expectations, which supported to the NZD/USD forex pair.


Indonesia’s manufacturing PMI rose to 51.9 in April, from 51.3 in the previous month. Despite the figure rising for the eighth month in a row, the IDR/USD pair remained under pressure in forex trading this morning.


US factory orders climbed 2.2% to $557.3 billion in March, recording the biggest increase since May 2021. However, the US dollar index traded flat this morning.

 

What’s happening: Shares of Pfizer rose on Tuesday, after the company reported better-than-expected results for its first quarter.

What happened: Pfizer maintained the sales estimates for its covid-19 vaccine, developed in collaboration with BioNTech, following several hikes to the projections over the past year.

However, the company recorded a decline in one of its major covid-19 treatments during the first quarter.

How were the results: The New York-based company reported strong growth in both sales and earnings for the first quarter.

  • Revenue jumped 77% to $25.66 billion, beating the Street expectations of $23.95 billion.
  • Adjusted earnings came in at $1.62 per share, up 72% year-over-year and well ahead of market estimates of $1.50 per share.

 

Why it matters: Despite a surge in covid-19 cases in some regions around the world, governments of the countries have been easing restrictions and relaxing masking rules.

Pfizer’s Comirnaty vaccine recorded sales of $13.2 billion, jumping 77% from a year ago and also topping the consensus estimates by over $2.6 billion. However, sales of its antiviral pill, Paxlovid, fell short of expectations by around $950 million.

Pfizer is looking to submit data to US regulators for the authorisation of its covid-19 vaccine for children below 5 years of age by early June. The pharma giant is also working on an update of its covid-19 vaccine to combat the Omicron strain.

Sales of the company’s pneumonia vaccine, Prevnar, and blood thinner, Eliquis, also grew by 59% and 12%, respectively during the quarter. Sales of its breast cancer treatment Ibrance declined, however, by 5% in the US due to more patients using a lower-cost program.

Pfizer reaffirmed its sales forecast of between $98 billion and $102 billion for fiscal 2022, which is below the consensus estimate of $107.94 billion. However, management lowered the adjusted earnings guidance from the prior forecast of $6.35-$6.55 per share to $6.25-$6.45 per share, citing new accounting requirements.

The company said it sees covid-19 vaccine sales of $32 billion and sales of its antiviral pill, Paxlovid, of around $22 billion for the year.

How shares responded: Pfizer’s shares gained 2% to close at $49.29 on Tuesday, following the release of quarterly results. The stock has lost around 13% year to date.

What to watch: Investors will keep an eye on rising covid-19 cases and developments around the approval of Pfizer’s vaccine for children under the age of five.

 

 

The markets today

Crude oil will be in focus today ahead of the EIA’s (Energy Information Administration) data on crude oil stockpiles

 

Context: Crude oil futures settled lower on Tuesday, as markets assessed the impact of China’s restrictions on energy demand.

Details: News of new hospital facilities getting ready in Beijing amid a spike in covid-19 cases in China raised fears of a decline in demand for crude oil in the weeks ahead. Despite new infections remaining low in China, the world’s largest oil importer, concerns of a lockdown in Beijing exerted pressure on oil prices.

The EU looking to place an embargo on crude imports from Russia, following the Ukraine invasion, lent some support to oil prices.

The S&P Global Ratings agency raised its WTI crude oil forecast from $80 per barrel to $85 per barrel for 2022 and from $65 per barrel to $70 per barrel for 2023. However, WTI prices are projected to fall to $50 per barrel in 2024.

WTI crude for June delivery shed $2.76, or 2.6%, to settle at $102.41 per barrel on the NYMEX on Tuesday. July Brent crude fell $2.61, or 2.4%, to close at $104.97 per barrel on ICE Futures Europe.

What to watch: Investors await the release of the EIA’s data on crude oil stockpiles. US crude oil inventories, which grew by 0.692 million barrels to 414.4 million barrels in the week ending April 22, are expected to decline by 0.829 million in the latest week. The US Fed’s interest rate decision will also remain in focus today, with expectations of a hike to 1%.

Markets will also keep an eye on rising covid-19 cases, the ongoing Russia-Ukraine tensions and accelerating inflation.

Other Markets: European trading indices closed higher on Tuesday, with the FTSE 100, DAX 40, CAC 40 and STOXX Europe 600 up by 0.22%, 0.72%, 0.79% and 0.53%, respectively.

Support & resistances for today

Technical Levels News Sentiment
EUR/GBP – 0.8425 and 0.8429 Positive
NZD/USD – 0.6447 and 0.6455 Positive
WTI Crude Oil – 103.30 and 103.46 Positive
Natural Gas – 7.780 and 7.797 Negative
Nasdaq 100 – 13041.05 and 13122.23 Positive

Market snapshot

What else to watch today

Germany’s balance of trade, services PMI and composite PMI, Russia’s manufacturing PMI, Eurozone’s services PMI, composite PMI, retail sales and ECB’s non-monetary policy meeting, Spain’s unemployment change, services PMI and composite PMI, Italy’s services PMI and composite PMI, France’s services PMI, composite PMI and retail sales, Brazil’s IPC-Fipe inflation, services PMI and composite PMI, UK’s mortgage approvals, mortgage lending, consumer credit and net lending to individuals, Mexico’s consumer confidence, US MBA mortgage applications, ADP Employment change, balance of trade, exports, imports, composite PMI, services PMI, ISM services PMI, gasoline inventories, distillate stockpiles, Cushing crude oil stocks, heating oil stocks, and new light-vehicle sales, India’s money supply M3 and central government budget value, as well as Canada’s balance of trade.

ADS Securities London Limited “ADSS” is an execution-only service provider. This material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or investment objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by ADSS that any particular investment, security, transaction or investment strategy is suitable for any specific person. To the extent that any content in this material is construed as investment research, you must note and accept that the content was not prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. This material may contain links to third party websites, and any content, or use of your personal data by any third party websites is not the responsibility of ADSS or any member of the ADSS Group.


Site by Pink Green
© ADSS 2022


CFDs and Spreadbets are complex instruments and come with a high risk of losing money rapidly due to leverage. 73% of Retail investor accounts lose money when trading CFDs and Spread Bets with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

ADSS is a trading name of ADS Securities London Limited, a company registered in England and Wales with company number 07785265 (VAT Registration Number: 212722447). Registered address 9th Floor, 125 Old Broad Street, London, EC2N 1AR. ADS Securities London Limited is authorised and regulated in the UK by the Financial Conduct Authority (FRN 577453).

The information on this site is not directed at residents of the United States, Canada, EU or any particular country outside the UK, and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law.

All opinions, news, analysis, prices or other information contained on this website are provided as general market commentary and does not constitute investment advice, nor a solicitation or recommendation for you to buy or sell any over-the-counter product or other financial instrument. Please ensure you understand all risks and seek independent advice if necessary.